Gilead(GILD) and Abbott(ABT) Guidance Triggers Biotech Sell-Off
Healthcare Reform Impact on Gilead HIV Product Sales Surprises Analysts Gilead Sciences (GILD) lowered its 2010 sales forecast to a range of $7.4-$7.5B from $7.6-$7.8B citing recently enacted healthcare legislation. Net income for the quarter ended March 31 jumped from $854.9M or $0.92/sh....
Genomics Update from AACR: Biomarkers for Oncology Medicine
Yesterday we presented an overview of the use of Biomarkers(BM's) for predictive use in the treatment of Lung Cancer. Here are some additional summaries from the American Association for Cancer Research(AACR) meeting on Monday.Researchers from Fox Chase Cancer Center in Philadelphia reported...
Helicos(HLCS) Update
GenomeWeb published an update (scroll down)on Helicos on Friday April 16. Full Year Revenues for fiscal 2009 were $3M and although R&D and Admin expenses were cut the Net Loss for the Year was $28M. Helicos has been working with the investment bank Thomas Weisel Partners since last summer...
Genomics Update: Biomarkers Help Select Personalized Oncology Medicine
At yesterday's AACR (American Association of Cancer Research) Meeting in Washington DC researchers presented results from the Battle Trial which is a hypothesis- driven prospective study that identifies biomarkers(BM's) to predict tumor response and thus helps select personalized therapy for...
Goldman Charge Curbs Enthusiasm for Market Risk
Larger Cap Healthcare Stocks Holding Up Well The SEC charges against Goldman Sachs have taken the MO out of the market with speculative issues down considerably. As of midday trading the Dow is down 1.2%. NASDAQ down 1.5% and the S&P down 1.6%.Stocks are off their lows. Large Cap healthcare...